Time filter

Source Type

Shioiri M.,Awa Medical Association Hospital | Kojima K.,Awa Medical Association Hospital | Yamamoto S.,Awa Medical Association Hospital | Watanabe Y.,Awa Medical Association Hospital | And 2 more authors.
Japanese Journal of Cancer and Chemotherapy | Year: 2010

XELOX for metastatic colorectal cancer has been approved last year in Japan and used to manage some cases of metastatic colorectal cancer at our hospital. We thought that this regimen has some merits in the patient's quality of life (QOL). Case 1: A 66-year-old man who had been diagnosed sigmoid colon cancer with retroperitoneal invasion. Case 2: A 67-year-old man who had been diagnosed Sigmoid colon cancer with multiple lung metastases. Therefore, both of them have been diagnosed as metastatic sigmoid colon cancer. Although two cases started with XELOX + bevacizumab, there was no toxicity of grade 3 or 4 for both, and we thought that the patients' QOL had been kept. Now, two cases are followed tightly as their chemotherapeutic response is being PR or NC.

Discover hidden collaborations